BioXcel Therapeutics (NASDAQ:BTAI) outlined its commercial strategy and launch preparations for IGALMI as it awaits a U.S. Food and Drug Administration decision on an expanded label for at-home treatment of acute agitation episodes associated with bipolar disorder and schizophrenia. The company is working toward a November 14 PDUFA target action date for its supplemental new drug application (sNDA), with plans to launch in the first quarter of 2027 if approved, executives said during a webcast moderated by Rodman & Renshaw biotechnology analyst Michael King.
Company sets the stage for at-home expansion
Chief Executive Officer and founder Vimal Mehta said BioXcel is in a “key period” as it prepares for the FDA’s decision and continues “launch readiness activities” to bring IGALMI to patients and caregivers “as efficiently as possible, if approved.” He emphasized that acute agitation episodes often occur outside clinical settings, where “there are currently no FDA-approved therapies,” describing the home setting as an unmet need.
Market research points to frequent episodes and limited options
Pavao said BioXcel’s market research included outreach to physicians, patients, and payers, and highlighted that agitation at home can be common even among patients whose underlying conditions are otherwise controlled. He cited research estimates that:
- 36% of bipolar patients who are “well-controlled” on mood stabilizers experience breakthrough agitation.
- 50% of schizophrenia patients who are “well-controlled” on antipsychotics experience breakthrough agitation.
He described acute agitation symptoms as spanning emotional (tension and irritability), behavioral (restlessness and overactivity), and cognitive (impulsivity) domains. In the absence of labeled at-home therapies, he said physicians often “double down” on oral typical or atypical antipsychotics, which he characterized as slow-acting, or use benzodiazepines, which are controlled substances with other concerns.
According to Pavao, when physicians were shown IGALMI’s proposed at-home target product profile, they projected the product could be used in about 70% of appropriate at-home agitation cases among their schizophrenia and bipolar patients. Patients, he said, showed “very, very high interest” and projected use in about 80% of future episodes after discussing their experiences with emergency room treatment.
86 million addressable episodes cited for at-home setting
Pavao said BioXcel’s research suggested a sizable expansion in addressable market when shifting from institutional to at-home use. He estimated 2.3 million treated bipolar and schizophrenia patients have frequent acute agitation, defined in the research as 10 to 15 episodes per year. After additional screening for eligibility criteria similar to SERENITY At-Home, he said BioXcel arrived at roughly 1.8 million addressable patients.
Using an average of four episodes per month observed in the study population, Pavao estimated about 86 million addressable agitation episodes per year for at-home use, compared with about 16 million episodes per year in institutional settings. In response to King’s question about the disparity, Pavao said patients often avoid the emergency room because it is “not a pleasant experience,” and many “suffer in place” without escalation to hospitalization. He also said episodes vary in intensity, with about one-third mild, one-third moderate, and one-third severe, and that early treatment could help prevent escalation.
Launch plan: education, payer access, and a concentrated prescriber base
Pavao said BioXcel aims to “redefine the standard of care” by increasing recognition of at-home agitation, encouraging early treatment, and ultimately seeking inclusion in treatment pathways and guidelines. He compared an at-home option for agitation to “having the EpiPen on hand.”
In the pre-launch period, he said BioXcel plans to emphasize scientific communications, including abstracts, posters, and publications, and to build out medical affairs capabilities, including a medical affairs leader and eventually a team of medical science liaisons. He also said the company expects to invest in payer education and value proposition development to support broad formulary access, noting that payers may impose prior authorization aligned to label and potential quantity limits due to episodic use.
On the commercial footprint, Pavao said prescribing is concentrated, estimating that about 65% of the schizophrenia and bipolar opportunity is covered by fewer than 10,000 physicians. He suggested a sales force “somewhere in the 80 rep range” could cover that segment, and said the market follows an “80/20” dynamic, with prescribing even more concentrated than a typical 80/20 split.
Pricing, packaging, and safety considerations discussed
Pavao said BioXcel’s payer research included transparency about the current $105-per-film price for IGALMI, and he reported “no pushback” in those preliminary discussions. He also noted that IGALMI is currently packaged in units of 10 and 30, and said a 10-pack “sets up nicely for a monthly prescription.” He added that each film is individually sealed and has its own National Drug Code, which could allow pack-size changes “pretty quickly.”
Asked about overuse risks, Pavao said payers are likely to implement quantity limits and that a patient might have around 10 films on hand, though he stressed it was too soon to define. He also said dexmedetomidine, the active ingredient, is used in ICU settings and is not the type of drug he would expect to be misused, adding that if someone took more than intended, “the primary thing” would be tiredness. He pointed to SERENITY At-Home, saying 250 patients over three months self-administered IGALMI without medical supervision, covering more than 2,500 treated episodes.
On health economics, Pavao said BioXcel has not yet conducted formal HEOR work but plans to build models, acknowledging early models would be “hypothetical” until reinforced with post-approval real-world data. Regarding Medicaid access, he said Medicaid is “state-by-state” and the company would need to pursue formulary coverage across states, though he said protections exist for patients with severe mental illness.
Mehta said BioXcel is “exploring all opportunities” for launch execution, including potential partnerships or co-commercialization arrangements, and said external interest has increased as the company “de-risked” the opportunity through Phase III data, sNDA submission, and FDA acceptance. Looking beyond the at-home indication, Mehta also highlighted planned work for a second confirmatory Phase III trial in Alzheimer’s agitation, stating the company has FDA alignment on the protocol, has selected a contract research organization, and plans to announce timing when it can initiate the trial.
About BioXcel Therapeutics (NASDAQ:BTAI)
BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.
BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.
